Project Grant K99AI197383
- Federal Project Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $422,355 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 23, 2025, with completion targeted for June 30, 2027. The grant funds mechanistic and structural studies examining the signaling histidine kinase GacS from Pseudomonas aeruginosa, a nosocomial...
- Federal Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $452,769 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 11, 2025, to conduct research on the impact of BDGR-49 treatment on Venezuelan Equine Encephalitis Virus (VEEV) induced neurological sequelae. The research addresses a critical public health gap by...
- Federal Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $437,541 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 2, 2026, through January 31, 2028. The award supports the discovery and development of antisense therapeutic candidates targeting Clostridioides difficile infection (CDI), a leading cause of nosocomial...
- Federal Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $414,482 Project Grant award from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 24, 2025, with a completion date of June 30, 2027. The research focuses on developing an improved oncolytic virus therapeutic to treat glioblastoma, an aggressive brain cancer with poor prognosis. The project aims to...
- Federal Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $191,163 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 5, 2026 through January 31, 2028. The award supports research investigating the transmission dynamics and pathogenesis of contemporary Mayaro virus (MAYV) strains, with particular focus on...
- Federal Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $422,314 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective March 1, 2026 through January 31, 2031. This award supports fundamental research investigating specialized adaptations in flagellar-driven motility and chemosensory systems in the alpha-proteobacterium Sinorhizobium...
- Federal Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $832,818 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on August 1, 2025, with a completion date of July 31, 2030. The grant funds the Rural Water Filtration and Health (RWELL) Trial, a research initiative designed to expand safe water access and improve health outcomes...
- Federal Grant Award Summary Virginia Polytechnic Institute & State University received a $611,861 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period September 1, 2025 through August 31, 2030. The project investigates chromosomal rearrangements in Aedes aegypti mosquitoes, the primary vector for dengue, Zika, and other arboviral diseases affecting approximately...
- Federal Project Grant Award Summary Virginia Commonwealth University received a $138,861 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on May 7, 2026, with a completion date of April 30, 2028. The research investigates how Orientia tsutsugamushi, the bacterium responsible for scrub typhus, manipulates host cell pathways to evade immune responses and enable intracellular...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Virginia a Project Grant totaling $795,990 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on April 23, 2026, with a completion date of March 31, 2031. This award supports a comprehensive research initiative to identify and target antimicrobial resistance (AMR) gene superspreaders within hospital ecosystems. The project addresses the critical...
Virginia Polytechnic Institute & State University (Virginia Tech) received a $112,256 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 22, 2026, with completion targeted for March 31, 2027. The research investigates the epigenetic basis of monocyte exhaustion memory following sepsis, addressing a critical public health challenge wherein sepsis survivors experience prolonged immune dysfunction. The project delivers scientific research and analysis designed to characterize the transcriptional and epigenetic features of monocyte exhaustion, model how immune stressor characteristics influence innate memory states, and identify therapeutic strategies targeting DNA methylation pathways to restore healthy immune function in sepsis survivors. The research encompasses three primary aims: profiling unique transcriptional and epigenetic features of exhausted monocytes through integrative modeling; testing the hypothesis that TET2 (ten-eleven translocation methylcytosine dioxygenase 2) inhibition drives epigenetic changes in exhaustion and evaluating TET agonists as a therapeutic approach; and examining a novel DNMT3L isoform identified in septic monocytes to understand altered chromatin regulation. This investigator-initiated biomedical research contributes to the broader scientific understanding of infectious disease mechanisms and generates foundational knowledge toward developing therapeutic interventions for sepsis-associated immune dysfunction.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $112.3k | 4/24/26 |